



Optimizing Treatment of Parkinson's Disease

Guest Editors:

Dr. Dag Nyholm

Department of Neuroscience,
Neurology at Uppsala University,
75124 Uppsala, Sweden

Dr. Filip Bergquist

Department of Pharmacology at
Institute of Neuroscience and
Physiology, University of
Gothenburg, 41296 Gothenburg,
Sweden

Deadline for manuscript
submissions:

closed (5 November 2021)

Message from the Guest Editors

Effective treatments for symptomatic control of Parkinson's disease (PD) have developed during the last two decades. These include combinations of oral drugs as well as transdermal delivery and devices for subcutaneous and intestinal infusions that have been developed in parallel with deep-brain stimulation (DBS) for PD and other movement disorders.

The scope of this Special Issue "Optimizing Treatment of Parkinson's Disease" is the latest approaches for meeting the need of continuous individualization of the therapies.

Current research is expanding on optimization of treatment outcome in terms of efficacy, safety, and quality of life, and the rapid development of wearables and home-based monitoring technologies is encouraging.

We invite researchers in the field to submit original research and review articles including (but not limited to) studies on the fine-tuning of treatments in PD and other movement disorders using objective movement analysis, DBS, personalized and precision medicine, pharmacogenomics, bioinformatics, integrative computational approaches and clinical biomarker discovery.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)